Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis

Abstract

Our data showed that Type 1 diabetes was not associated with an increased prevalence of steatosis. Moreover, our study provided no specific arguments concerning a link between liver fat content and diabetic complications in patients with Type 1 diabetes.

Non‐alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes

“…6 In contrast, a magnetic resonance imaging (MRI) study reported a prevalence of only 4.7%. 7 The latter finding is consistent with a smaller MRI study showing lower LFC in T1D patients than in age-and body mass index (BMI)-matched healthy subjects. 8 The aim of this investigation was to assess the prevalence and clinical phenotype of NAFLD in patients with T1D and T2D.…”

“…However, ultrasound is significantly less accurate than magnetic resonance spectroscopy for the diagnosis of NAFLD . Another study using MRI reported a prevalence of NAFLD in T1D patients (4.7%) similar to that observed in our study, supporting the conclusion that the prevalence of NAFLD in T1D patients is low. Although NAFLD in T1D patients is not well‐studied, an observational survey reported that T1D patients with elevated liver enzymes had a less favourable cardiovascular risk profile and poorer glycaemic control …”

“…A recent study, in which NAFLD was diagnosed by ultrasonography, suggested a high prevalence of 50% in patients with type 1 diabetes (T1D) . In contrast, a magnetic resonance imaging (MRI) study reported a prevalence of only 4.7% . The latter finding is consistent with a smaller MRI study showing lower LFC in T1D patients than in age‐ and body mass index (BMI)‐matched healthy subjects …”

Low prevalence of non‐alcoholic fatty liver disease in patients with type 1 diabetes is associated with decreased subclinical cardiovascular disease

“…The prevalence of NAFLD in the present study, performed on a cohort of middle-aged Mediterranean T1D subjects, was intermediate compared with prevalence reported in previous studies. [14][15][16]18 In the present cohort, NAFLD was also associated with Grade 2 overweight, higher TG concentrations, and a higher proportion of statin treatment. Statistical analysis suggested that the presence of NAFLD was associated with higher CIMT, which indicates that systematic screening for NAFLD in T1D may be useful for the identification of subjects at risk not only for further hepatic disease, but also subclinical CVD.…”

“…Nevertheless, other studies have found a lower prevalence, not higher than 10%. 17,18 The high prevalence of NAFLD in T1D could be explained by the growing coexistence of MS and T1D, so-called "double diabetes," 19 which is related to intensive insulin treatment and the increase in obesity in T1D subjects, as in the general population. 20 The presence of NAFLD in T1D appears to be independently associated with macrovascular 15 and microvascular chronic complications.…”